Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
Globe Newswire (Thu, 21-May 7:30 AM ET)
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 15-May 4:00 PM ET)
Globe Newswire (Wed, 13-May 4:10 PM ET)
Globe Newswire (Fri, 17-Apr 4:00 PM ET)
Globe Newswire (Thu, 19-Mar 7:21 AM ET)
Globe Newswire (Tue, 17-Mar 5:54 PM ET)
Acrivon Therapeutics Faces Premarket Drop After Breakthrough Device Designation Announcement
Market Chameleon (Wed, 5-Feb 3:41 AM ET)
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.
As of June 11, 2026, ACRV stock price climbed to $1.44 with 322,624 million shares trading.
ACRV has a beta of 2.00, meaning it tends to be more sensitive to market movements. ACRV has a correlation of 0.10 to the broad based SPY ETF.
ACRV has a market cap of $61.63 million. This is considered a Micro Cap stock.
Last quarter Acrivon Therapeutics reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-498,304 and exceeded earnings estimates by $.02.
In the last 3 years, ACRV traded as high as $14.03 and as low as $1.05.
The top ETF exchange traded funds that ACRV belongs to (by Net Assets): VTI, VXF, IWC.
ACRV has underperformed the market in the last year with a price return of +12.5% while the SPY ETF gained +23.6%. ACRV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.3% and -13.3%, respectively, while the SPY returned +9.2% and -1.7%, respectively.
ACRV support price is $1.31 and resistance is $1.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV shares will trade within this expected range on the day.